In 4Q16, Celgene’s (CELG) Abraxane maintained its dominant position as a first-line metastatic pancreatic cancer therapy in the US. The drug also witnessed stable demand for lung and breast cancer. Abraxane has also been witnessing a gradual rise in overall demand in metastatic breast cancer as well as in metastatic pancreatic cancer segments in Europe.
In 4Q16, Abraxane’s sales reached ~$266 million, which represents a fall of ~1% on a YoY (year-over-year) basis. The drug earned ~$171 million in the US, which represents a YoY fall of about 5%. In 4Q16, Abraxane earned revenues of $95 million in international markets, which represents a YoY growth of ~5%. For 2016, Pomalyst reported revenues worth $973 million, which represents a YoY growth of ~1%.
Celgene expects data from its Phase-3 Apact trial, which evaluates Abraxane as an adjuvant therapy for pancreatic cancer, by the end of 2017. The company also expects to expand Abraxane’s label as a monotherapy or in combination with immune-oncology agents in multiple oncology indications. In this way, Celgene would be posing tough competition for oncology players like Pfizer (PFE), Merck (MRK), and Eli Lilly (LLY).
Notably, the Health Care Select Sector SPDR ETF (XLV) has ~3.1% of its total portfolio in CELG. To know more about the demand trends for Abraxane, please refer to Market Realist’s “Abraxane Is Still Witnessing Robust Demand in Solid Tumor Segment.”
Now let’s analyze the growth trends for Celgene’s Otezla.